-

ATS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into ATS Corporation (ATS)

ATS Corporation missed Q1 fiscal 2027 consensus revenue by roughly C$30 million and the stock declined more than 26%. Levi & Korsinsky is investigating potential securities law violations on behalf of ATS investors who lost money.

NEW YORK--(BUSINESS WIRE)--ATS Corporation (NYSE: ATS) reported Q1 fiscal 2027 revenue of C$693.7 million against the C$724.0 million FactSet consensus estimate -- a shortfall of approximately C$30.3 million -- and shares declined about 26.55% following the report. If you lost money on ATS shares, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Revenue fell 5.8% year over year. Adjusted EBITDA declined 8.5%. a combination of timing of project execution, a more normalized level of GLP-1-related activities compared to the prior-year period, and the impacts of the restructuring activities within the Company's transportation businesses.

The reported figure also came in approximately C$6.3 million below the low end of the C$700 million to C$740 million range Interim CFO Michael Anne Cybulski provided on the Q4 fiscal 2026 earnings call held May 28, 2026. Alongside the results, management announced an 18-month fixed-cost transformation program.

Shareholders who purchased ATS securities and suffered losses are encouraged to have their claim evaluated at no cost, or contact Joseph E. Levi, Esq. at (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the ATS Investigation

Q: How much did ATS stock drop? A: Shares fell by $7.42 (26.55%) to close at approximately $20.53 per share on August 6, 2026, following the reveal of ATS’ first quarter results. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: Who is eligible to participate in the ATS investigation? A: Investors who purchased ATS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether ATS Corporation adequately disclosed the demand, backlog conversion, and fixed-cost pressures that were reflected in the Q1 fiscal 2027 revenue shortfall and swing to a net loss. It further concerns whether investors were adequately risked as to the purported need for the 18-month transformation program, in light of ongoing restructuring efforts.

Q: What do ATS investors need to do right now? A: Gather brokerage records showing purchase dates, share quantities, and prices paid, then contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ATS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ATS and sold at a loss may still participate.

Q: What does it cost me to participate? A: There is no upfront cost. These matters are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NYSE:ATS

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The revenue shortfall came alon...

LZ Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into LegalZoom.com, Inc. (LZ)

NEW YORK--(BUSINESS WIRE)--LegalZoom.com, Inc. (NASDAQ: LZ) shares dropped after the Company's August 5 second-quarter release, in which adjusted earnings per share came in at $0.16 versus the $0.15 consensus -- while full-year revenue guidance was reduced to approximately $795 million to $805 million from $810 million to $830 million. If you lost money on LZ shares, click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telep...

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)

NEW YORK--(BUSINESS WIRE)--Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. If you suffered a loss on your Emergent BioSolutions investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. NARCAN Nasal...
Back to Newsroom